These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 872378)

  • 21. Liquid chromatography in the monitoring of plasma levels of antiarrhythmic drugs.
    Lagerström PO; Persson BA
    J Chromatogr; 1978 Feb; 149():331-40. PubMed ID: 649734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of desethyl procainamide in patients: a new metabolite of procainamide.
    Ruo TI; Morita Y; Atkinson AJ; Henthorn T; Thenot JP
    J Pharmacol Exp Ther; 1981 Feb; 216(2):357-62. PubMed ID: 6162026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversed-phase liquid chromatography method for measurement of procainamide and three metabolites in serum and urine: percent of dose excreted as deethyl metabolites.
    Coyle JD; MacKichan JJ; Boudoulas H; Lima JJ
    J Pharm Sci; 1987 May; 76(5):402-5. PubMed ID: 2443639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liquid-chromatographic determination of antidysrhythmic drugs: procainamide, lidocaine, quinidine, disopyramide, and propranolol.
    Kabra PM; Chen SH; Marton LJ
    Ther Drug Monit; 1981; 3(1):91-101. PubMed ID: 7233493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous liquid-chromatographic determination of five antiarrhythmic drugs and their major active metabolites in serum.
    Proelss HF; Townsend TB
    Clin Chem; 1986 Jul; 32(7):1311-7. PubMed ID: 3087659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of procainamide and N-acetylprocainamide by "high-performance" liquid chromatography.
    Stearns FM
    Clin Chem; 1981 Dec; 27(12):2064-7. PubMed ID: 6171366
    [No Abstract]   [Full Text] [Related]  

  • 28. Analysis for procainamide and N-acetyl procainamide in plasma or serum by high-performance liquid chromatography.
    Rocco RM; Abbott DC; Giese RW; Karger BL
    Clin Chem; 1977; 23(4):705-8. PubMed ID: 844165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of sematilide in plasma by high-performance liquid chromatography.
    Dancik S; Koziol T; Nisperos E; Woolf E
    J Pharm Sci; 1991 Feb; 80(2):157-9. PubMed ID: 2051320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation.
    Zema MJ; Mirando T
    Angiology; 1983 Jan; 34(1):32-9. PubMed ID: 6186164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of Fluoroimmunoassays for the determination of individual or combined levels of procainamide and N-acetylprocainamide in serum.
    Al-Hakiem MH; Smith DS; Landon J
    J Immunoassay; 1982; 3(1):91-110. PubMed ID: 6182162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid determination of procainamide and its N-acetyl derivative in human plasma by high-pressure liquid chromatography.
    Weddle OH; Mason WD
    J Pharm Sci; 1977 Jun; 66(6):874-5. PubMed ID: 874793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Four fluorescence polarization immunoassays for therapeutic drug monitoring evaluated.
    Haver VM; Audino N; Burris S; Nelson M
    Clin Chem; 1989 Jan; 35(1):138-40. PubMed ID: 2463117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assay of serum procainamide and N-acetylprocainamide: a comparison of emit and reverse-phase high-performance liquid chromatography.
    Griffiths WC; Dextraze P; Hayes M; Mitchell J; Diamond I
    Clin Toxicol; 1980 Mar; 16(1):51-4. PubMed ID: 6156051
    [No Abstract]   [Full Text] [Related]  

  • 35. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide.
    Vlasses PH; Kosoglou T; Chase SL; Greenspon AJ; Lottes S; Andress E; Ferguson RK; Rocci ML
    Arch Intern Med; 1989 Jun; 149(6):1350-3. PubMed ID: 2471472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiarrhythmic potency of N-acetylprocainamide.
    Elson J; Strong JM; Lee WK; Atkinson AJ
    Clin Pharmacol Ther; 1975 Feb; 17(2):134-40. PubMed ID: 1122675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of evoked endocardial response for assessment of antiarrhythmic drug effects on myocardium.
    Furukawa T; Taniguchi K; Takeuchi J
    Bull Tokyo Med Dent Univ; 1988 Sep; 35(3):33-44. PubMed ID: 2466578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-performance liquid chromatography of quinidine in plasma, with use of a microparticulate silica column.
    Peat MA; Jennison TA
    Clin Chem; 1978 Dec; 24(12):2166-8. PubMed ID: 719865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous determination of antiarrhythmia drugs by high-performance thin-layer chromatography.
    Lee KY; Nurok D; Zlatkis A
    J Chromatogr; 1978 Oct; 158():403-10. PubMed ID: 721938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of antiarrhythmic effects of procainamide, N-acetylprocainamide, and p-hydroxy-N-(3-diethylaminopropyl)benzamide.
    Reynolds RD; Burmeister WE; Calzadilla SV; Lee RJ; Reidenberg MM; Drayer DE
    Proc Soc Exp Biol Med; 1982 Feb; 169(2):156-60. PubMed ID: 6174988
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.